Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints

(RTTNews) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with moderate-to-severe active Thyroid Eye Disease. The trial met its primary endpoint in moderate-to-severe active TED, showing a statistically significant and clinically meaningful 77% proptosis response rate during the 24-week placebo-controlled period. Full results will be presented at an upcoming medical congress.

"These results extend and support the best-in-class efficacy of TEPEZZA for people living with Thyroid Eye Disease, now with subcutaneous administration delivering IV-level efficacy," said Jay Bradner, executive vice president of Research and Development at Amgen.

Amgen shares are currently trading at $344.11, down 1.10 percent.

For More Such Health News, visit rttnews.com.